Subtopic Deep Dive
Cardiac Fibrosis Mechanisms
Research Guide
What is Cardiac Fibrosis Mechanisms?
Cardiac fibrosis mechanisms encompass the cellular and molecular processes driving excessive extracellular matrix deposition by activated fibroblasts in response to cardiac injury.
Myofibroblast activation and endothelial-to-mesenchymal transition (EndMT) contribute to fibrosis post-myocardial infarction (Zeisberg et al., 2007, 2148 citations). Inflammatory signaling and TGF-β pathways regulate ECM remodeling (Frangogiannis, 2002, 1979 citations; Kong et al., 2013, 1517 citations). Over 10 key papers from 1997-2020 detail these pathways using transgenic models and human heart samples.
Why It Matters
Targeting fibrosis mechanisms halts heart failure progression, as fibroblasts drive ECM accumulation in nearly all heart diseases (Travers et al., 2016, 1495 citations). Frangogiannis (2020, 1015 citations) shows reparative fibrosis protects against rupture but becomes pathological, enabling therapies like TGF-β inhibitors. Zeisberg et al. (2007) link EndMT to fibrosis, informing anti-fibrotic drugs that reduce mortality in ischemic cardiomyopathy (Frangogiannis, 2002).
Key Research Challenges
Heterogeneity of Fibroblast Sources
Fibroblasts arise from resident cells, EndMT, or epicardial EMT, complicating targeted inhibition (Zeisberg et al., 2007; Souders et al., 2009, 960 citations). Kong et al. (2013) highlight varying origins post-injury, hindering uniform therapies.
TGF-β Signaling Complexity
TGF-β activates myofibroblasts but crosstalk with inflammation obscures inhibition points (Frangogiannis, 2020). Travers et al. (2016) note pathway redundancy leads to fibrosis rebound.
Translating Models to Humans
Mouse transgenic models show fibrosis but human hearts exhibit apoptosis-driven remodeling (Olivetti et al., 1997, 1680 citations). Shiojima (2005, 924 citations) reveals angiogenesis-fibrosis mismatch absent in simple models.
Essential Papers
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Elisabeth M. Zeisberg, Oleg Tarnavski, Michael Zeisberg et al. · 2007 · Nature Medicine · 2.1K citations
The inflammatory response in myocardial infarction
Nikolaos G. Frangogiannis · 2002 · Cardiovascular Research · 2.0K citations
One of the major therapeutic goals of modern cardiology is to design strategies aimed at minimizing myocardial necrosis and optimizing cardiac repair following myocardial infarction. However, a sou...
Apoptosis in the Failing Human Heart
G Olivetti, Rakesh Abbi, Federico Quaini et al. · 1997 · New England Journal of Medicine · 1.7K citations
Programmed death of myocytes occurs in the decompensated human heart in spite of the enhanced expression of BCL2; this phenomenon may contribute to the progression of cardiac dysfunction.
The pathogenesis of cardiac fibrosis
Ping Kong, Panagiota Christia, Nikolaos G. Frangogiannis · 2013 · Cellular and Molecular Life Sciences · 1.5K citations
Cardiac Fibrosis
Joshua G. Travers, Fadia Kamal, Jeffrey Robbins et al. · 2016 · Circulation Research · 1.5K citations
Myocardial fibrosis is a significant global health problem associated with nearly all forms of heart disease. Cardiac fibroblasts comprise an essential cell type in the heart that is responsible fo...
Molecular Mechanisms of Myocardial Remodeling
Bernard Swynghedauw · 1999 · Physiological Reviews · 1.5K citations
Swynghedauw, Bernard. Molecular Mechanisms of Myocardial Remodeling. Physiol. Rev. 79: 215–262, 1999. — “Remodeling” implies changes that result in rearrangement of normally existing structures. Th...
Heart repair by reprogramming non-myocytes with cardiac transcription factors
Kunhua Song, Young-Jae Nam, Xiang Luo et al. · 2012 · Nature · 1.1K citations
Reading Guide
Foundational Papers
Start with Zeisberg et al. (2007, 2148 citations) for EndMT mechanism, Frangogiannis (2002, 1979 citations) for post-MI inflammation, and Kong et al. (2013, 1517 citations) for pathogenesis overview.
Recent Advances
Study Frangogiannis (2020, 1015 citations) for updated fibrosis dynamics and Travers et al. (2016, 1495 citations) for fibroblast roles.
Core Methods
Core techniques: transgenic lineage tracing, TGF-β/Smad signaling assays, ECM quantification via Sirius Red staining (Zeisberg et al., 2007; Souders et al., 2009).
How PapersFlow Helps You Research Cardiac Fibrosis Mechanisms
Discover & Search
Research Agent uses searchPapers for 'cardiac fibrosis TGF-β mechanisms' yielding Zeisberg et al. (2007), then citationGraph traces 2148 citations to Kong et al. (2013), and findSimilarPapers uncovers Frangogiannis (2020). exaSearch scans 250M+ papers for recent EndMT inhibitors.
Analyze & Verify
Analysis Agent applies readPaperContent to Travers et al. (2016), verifyResponse with CoVe cross-checks TGF-β claims against Frangogiannis (2002), and runPythonAnalysis plots citation timelines or ECM gene expression from supplements using pandas. GRADE grading scores evidence strength for myofibroblast activation pathways.
Synthesize & Write
Synthesis Agent detects gaps in EndMT therapies post-Zeisberg (2007), flags contradictions between mouse and human data (Olivetti et al., 1997). Writing Agent uses latexEditText for figure legends, latexSyncCitations for 10-paper bibliography, latexCompile for review draft, and exportMermaid for TGF-β signaling diagrams.
Use Cases
"Extract fibroblast activation timelines from post-MI papers"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Frangogiannis 2002) → runPythonAnalysis (pandas timeline plot) → researcher gets temporal heatmap of inflammatory to fibrotic phases.
"Draft LaTeX review on EndMT in fibrosis"
Research Agent → citationGraph (Zeisberg 2007) → Synthesis → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → researcher gets compiled PDF with figures and 20 citations.
"Find code for cardiac fibroblast RNA-seq analysis"
Research Agent → paperExtractUrls (Travers 2016) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets validated GitHub repo with differential expression scripts.
Automated Workflows
Deep Research workflow scans 50+ fibrosis papers via searchPapers, structures report on mechanisms with GRADE scores, chaining to DeepScan for 7-step verification of TGF-β data from Kong et al. (2013). Theorizer generates hypotheses on EndMT inhibitors by synthesizing Zeisberg (2007) and Song (2012, 1129 citations).
Frequently Asked Questions
What defines cardiac fibrosis mechanisms?
Processes include myofibroblast transdifferentiation, EndMT, and ECM deposition via TGF-β after injury (Zeisberg et al., 2007; Travers et al., 2016).
What are key methods studied?
Transgenic mouse models, inhibitors of TGF-β, and human heart histology dissect pathways (Frangogiannis, 2002; Kong et al., 2013).
What are seminal papers?
Zeisberg et al. (2007, 2148 citations) on EndMT; Frangogiannis (2020, 1015 citations) on fibrosis phases; Travers et al. (2016, 1495 citations) on fibroblasts.
What open problems remain?
Specific fibroblast lineage tracing in humans and safe TGF-β blockade without impairing repair (Frangogiannis, 2020; Shiojima, 2005).
Research Cardiac Fibrosis and Remodeling with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cardiac Fibrosis Mechanisms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cardiac Fibrosis and Remodeling Research Guide